A Taliansky1,2, O Furman3, M Gadot3, D Urban3,4, J Bar3,4, R Shapira-Frumer3,4, B Kaufman3,4, N Asher3,4, R Leibowitz-Amit3,4, A Itay3,4. 1. Institute of Oncology, Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel. Alisa31@netvision.net.il. 2. Tel Aviv University Medical School, Tel Aviv, Israel. Alisa31@netvision.net.il. 3. Institute of Oncology, Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel. 4. Tel Aviv University Medical School, Tel Aviv, Israel.
Abstract
BACKGROUND: Treatment with immune checkpoint inhibitors (ICI) has greatly improved survival for patients with a number of malignant diseases in recent years. Neurological immune-related adverse events (n-irAE) of varying severity have been reported in the literature. We aimed to identify the incidence of n-irAE, focusing on immune-related encephalitis (IRE), in patients treated with ICI for multiple non-hematological malignancies in our institution. METHODS: All patients with histologically verified cancer that received treatment with ICI at the Sheba Medical Center between January 2017 and August 2019 were surveyed. Medical records for each patient were reviewed and information regarding n-irAE was recorded. RESULTS: In total, 1993 patients were included. Eleven cases of IRE were recorded, affecting 0.55% of patients overall, eight had non-melanoma cancer. Eight patients had made a full recovery. CONCLUSIONS: IRE is a n-irAE more frequent than previously reported, particularly in non-melanoma patients. The diagnostic criteria and optimal treatment needs to be determined. ICI re-challenge after IRE can be considered for selected patients.
BACKGROUND: Treatment with immune checkpoint inhibitors (ICI) has greatly improved survival for patients with a number of malignant diseases in recent years. Neurological immune-related adverse events (n-irAE) of varying severity have been reported in the literature. We aimed to identify the incidence of n-irAE, focusing on immune-related encephalitis (IRE), in patients treated with ICI for multiple non-hematological malignancies in our institution. METHODS: All patients with histologically verified cancer that received treatment with ICI at the Sheba Medical Center between January 2017 and August 2019 were surveyed. Medical records for each patient were reviewed and information regarding n-irAE was recorded. RESULTS: In total, 1993 patients were included. Eleven cases of IRE were recorded, affecting 0.55% of patients overall, eight had non-melanoma cancer. Eight patients had made a full recovery. CONCLUSIONS: IRE is a n-irAE more frequent than previously reported, particularly in non-melanoma patients. The diagnostic criteria and optimal treatment needs to be determined. ICI re-challenge after IRE can be considered for selected patients.
Authors: M Hardy-Werbin; O Arpí; A Taus; P Rocha; D Joseph-Pietras; L Nolan; S Danson; R Griffiths; M Lopez-Botet; A Rovira; J Albanell; C H Ottensmeier; E Arriola Journal: Oncoimmunology Date: 2017-11-27 Impact factor: 8.110
Authors: Jordi Bruna; Andreas A Argyriou; Garifallia G Anastopoulou; Montse Alemany; Ernest Nadal; Foteini Kalofonou; Josep M Piulats; Marta Simó; Roser Velasco; Haralabos P Kalofonos Journal: J Peripher Nerv Syst Date: 2020-03-24 Impact factor: 3.494
Authors: L Spain; G Walls; M Julve; K O'Meara; T Schmid; E Kalaitzaki; S Turajlic; M Gore; J Rees; J Larkin Journal: Ann Oncol Date: 2017-02-01 Impact factor: 32.976
Authors: S Cuzzubbo; F Javeri; M Tissier; A Roumi; C Barlog; J Doridam; C Lebbe; C Belin; R Ursu; A F Carpentier Journal: Eur J Cancer Date: 2017-01-05 Impact factor: 9.162
Authors: Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson Journal: J Clin Oncol Date: 2018-02-14 Impact factor: 44.544
Authors: John A Thompson; Bryan J Schneider; Julie Brahmer; Stephanie Andrews; Philippe Armand; Shailender Bhatia; Lihua E Budde; Luciano Costa; Marianne Davies; David Dunnington; Marc S Ernstoff; Matthew Frigault; Brianna Hoffner; Christopher J Hoimes; Mario Lacouture; Frederick Locke; Matthew Lunning; Nisha A Mohindra; Jarushka Naidoo; Anthony J Olszanski; Olalekan Oluwole; Sandip P Patel; Sunil Reddy; Mabel Ryder; Bianca Santomasso; Scott Shofer; Jeffrey A Sosman; Momen Wahidi; Yinghong Wang; Alyse Johnson-Chilla; Jillian L Scavone Journal: J Natl Compr Canc Netw Date: 2019-03-01 Impact factor: 11.908